Search

Your search keyword '"Bastús, Romà"' showing total 11 results
Start Over Author "Bastús, Romà"
11 results on '"Bastús, Romà"'

2. Bladder cancer in the textile industry

Author

Working Group on the Study of Bladder Cancer in the County of Vallès Occidental, Serra, Consol, Bonfill, Xavier, Sunyer, Jordi, Urrutia, Gerard, Turuguet, Domènech, Bastús, Romà, Roqué, Marta, 't Mannetje, Andrea, and Kogevinas, Manolis

Published
2000

7. A Risk-Adapted Approach to Patients with Stage I Seminoma according to the Status of Rete Testis: The Fourth Spanish Germ Cell Cancer Group Study.

Author

Aparicio, Jorge, Sagastibelza, Naiara, Ochenduszko, Sebastián, Sánchez, Alfredo, Terrasa, Josefa, Germà-Lluch, Josep R., García del Muro, Xavier, Sánchez-Muñoz, Alfonso, Gumà, Josep, Domenech, Montserrat, Meana, José A., García-Sánchez, José, Bastús, Romà, Gironés, Regina, and González-Billalabeitia, Enrique

Subjects
ETOPOSIDE, BLEOMYCIN, CARBOPLATIN, ADJUVANT treatment of cancer, CANCER relapse, CANCER invasiveness, CASTRATION, CHORIONIC gonadotropins, LONGITUDINAL method, MEDICAL cooperation, POSTOPERATIVE period, RESEARCH, RISK assessment, SURVIVAL, TESTIS, TUMOR classification, TREATMENT effectiveness, PREOPERATIVE period, KAPLAN-Meier estimator, SEMINOMA, TERTIARY care, CHEMORADIOTHERAPY, DISEASE risk factors, THERAPEUTICS
Abstract

Objective: The aim of this study was to assess a risk-adapted strategy for stage I seminoma guided by the presence of rete testis invasion. Methods: Between January 2013 and December 2015, a total of 135 consecutive patients with stage I seminoma from 18 Spanish tertiary hospitals were included in a prospective multicenter study. Median patient age was 38 years (range 22–60). Preoperative beta-human chorionic gonadotropin was elevated in 9.6% of patients. Rete testis invasion was present in 47.4% of patients. After orchiectomy, subjects with rete testis invasion were treated with 2 courses of adjuvant carboplatin (area under the curve of 7, with 21-day interval). Those without this risk factor were managed by surveillance. Disease-free survival (DFS) and overall survival (OS) were estimated with the Kaplan-Meier method. Results: After a median follow-up time of 33 months, only 6 relapses were recorded (5 on surveillance, 1 after carboplatin). These cases were rescued with BEP or EP chemotherapy, and all 135 patients are currently disease free without sequelae. Three-year DFS was 92.0 and 98.2% for patients on surveillance and after carboplatin, respectively. Three-year OS was 100%. Conclusion: A risk-adapted approach based on rete testis invasion as a single risk factor is feasible and yielded an excellent outcome with a 3-year DFS of 94.9%. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results